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In 2009 news media regularly reported examples of adverse 
events in a public health system that, many would argue, is 
in crisis, with widespread work stoppages by overworked 
doctors, shut-down of critical units in hospitals, shortages of 
vitally needed supplies and equipment – all of which result in 
denial of treatment to patients or, at best, inadequate treatment. 
Newly appointed health minister Dr Aaron Motsoaledi 
honestly conceded that the public health system faces ‘very 
serious challenges’.1
Many of these failures can be attributed to a combination 
of limited resources and management incompetence, but the 
burden of HIV/AIDS presents another serious, long-term 
problem that has contributed to a crumbling public health 
system. During the recent era of denialism and obfuscation, 
the government refused to provide life-saving antiretrovirals 
(ARVs) to hundreds of thousands of people living with 
HIV/AIDS. In 2003, under intense political pressure, the 
government began to increase spending on HIV treatment, and 
in 2009/2010 will spend R11.4 billion2 or approximately 13% of 
the R87 billion allocated to health in the 2009/10 budget.3 In its 
2007 HIV Plan, the Department of Health set a goal of treating 
80% of those who need ARVs by 2011.4
The associated cost estimates are staggering, with one 
projection putting HIV expenditure over 5 years at US$6.4 
billion (about R52 billion). Overall annual spending on HIV 
may eventually exceed 20% of the entire national health 
budget.4 Yet even these scaled-up budgets have fallen short: 
the Deputy Chair of the National AIDS Council reported that 
the health budget would need an extra R1 billion for ARVs as 
the number of infected patients needing treatment grows.5 The 
former Minister of Health estimated that 1.5 million people 
would need ARVs by 2011, and confirmed that South Africa 
would need sustainable donor help to meet these needs.6
While it is encouraging that the government has finally 
recognised the scope of the problem of treating the nation’s 
growing HIV population, it is important to note that the 
drastic growth in HIV treatment spending has taken place in 
the context of a largely static national health budget.7 As the 
budget for providing treatment to the enormous number of 
people living with AIDS continues to increase, policy makers 
must face a troubling question: what is the impact of this 
massively scaled-up spending on HIV treatment on the public 
health system? Is it possible that increased funding to meet the 
government’s 80% goal will displace (or ‘crowd out’) resources 
critically needed to meet other pressing health priorities? 
Although this is a disturbing question, commentators 
elsewhere in the world have raised the issue8 and South 
Africa’s policy makers cannot afford a head-in-the-sand 
approach to what is not only a major public health but also a 
moral and political issue. 
Given that many patients needing treatment are in the prime 
of life, and that compliant treatment with ARVs can result 
in prolonging good-quality life for many years, we believe 
that the government’s scaled-up spending on HIV treatment 
is necessary. In addition, a number of recent studies have 
shown that providing reduced-price antiretroviral treatment 
may produce other positive impacts, such as reducing the 
clinical burden (and associated costs) of patients on ARVs on 
specific elements of the South African health system,9,10 but 
these positive impacts must be seen in the context of an overall 
health budget that has failed to meet other critical health needs. 
Between 1998 and 2006, annual per capita health expenditure 
has remained virtually constant in real terms, and small 
increases have not kept pace with the annual inflation rate, 
population growth, or the greatly increased burden of disease.6
As spending for HIV treatment has consumed an ever-larger 
proportion of the health budget, budgets for other services 
– including those that support treatment of many other chronic 
diseases – appear to have remained static. Underfunding of 
these services has contributed to the public sector’s diminished 
capacity to treat these diseases, as has occurred elsewhere.11 
For example, the burden of delivering HIV services to children 
has limited the scope of other critical paediatric services such 
as immunisations and treatment of other chronic conditions.12 
Similarly, because funding for HIV treatment constitutes a 
substantial portion of international health aid to developing 
countries, this may have limited the funding available for 
general and population health needs.13 
A contentious international debate is raging over whether 
increased donor and government funding directed specifically 
to HIV treatment has displaced or ‘crowded out’ funding for 
other diseases.14-16 Although it is of concern that, as funding 
for HIV increases, funding for other diseases appears not to 
have kept pace with growing needs, we believe that it would 
be premature to conclude that the government has diverted 
funding to HIV treatment that would otherwise have been 
directed to treatment of other diseases. However, if the current 
budgeting trend continues, and spending targeted at HIV 
increases substantially in future years while the overall budget 
grows at less than the rate of medical inflation, this would 
increase the possibility that HIV treatment spending would 
eventually produce adverse health outcomes for those who also 
need, and can benefit from, treatment for other diseases. Policy 
makers must be alert to this possible outcome, which is one 
that could be exacerbated as the cost of treating an expanding 
population of HIV patients over coming years rises drastically, 
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at the same time as demands for prevention and treatment of 
other major sources of illness and death continue to increase. 
It would be medically, politically and morally – and probably 
legally – unacceptable for expanded treatment of the HIV 
population to come at an unacceptable cost to patients who 
bear the burden of other chronic diseases and health conditions 
and could also benefit significantly from appropriate treatment, 
especially when more cost-effective HIV prevention options are 
readily available.17
If the overall health budget is not increased to take into 
account the needs of all patient populations, the government 
will face a seemingly irreconcilable resource allocation 
problem: how to respond to a moral and political imperative 
to ramp up HIV spending after years of non-intervention, 
while at the same time addressing rising demands to fund 
other equally compelling health priorities. Sadly, the history 
of the government’s resource allocation policy has been one 
of ad hoc, unplanned knee-jerk reaction to each crisis as it 
arises. Typically, peremptory budget cuts for other health 
services have been announced at short notice, without prior 
consultation with key stakeholders, and with the inevitable 
social, political and legal ramifications.18 
In an attempt to shift private resources to a deteriorating 
public health sector, the government has proposed the 
development of a form of National Health Insurance (NHI) 
administered by a new entity that would raise funds from the 
taxpayers and users of the private health sector to purchase 
health care benefits for the population. The Minister of Health 
has claimed that the NHI would deliver ‘universal coverage 
and better healthcare in one united healthcare system’.19 
Critics have argued that before implementing a policy that 
could cost up to 20% of South Africa’s GDP, the government 
must first fix the severe problems crippling its public health 
system, including its failure to use health resources efficiently 
and distribute them fairly.20 Yet the public health sector 
currently has no mechanism for fairly, rationally and efficiently 
allocating health resources among the many diverse patient 
populations who need and can benefit from treatment.
The perceived ad hoc, non-participatory and arbitrary 
distribution of resources has both undermined the morale of 
health professionals and challenged the credibility of health 
administrators. The question is, therefore, not whether we 
should stop increasing funding for HIV treatment until we can 
‘make up’ funding for other health services. Rather, we must 
ask: how can the government rationally, efficiently, and in a 
non-discriminatory fashion allocate its limited health resources 
among patients who have a bewilderingly wide variety of 
health needs? 
Notwithstanding the proven downstream primary health 
care benefits of certain HIV programmes,15 most would 
agree that limited resources should be fairly and rationally 
allocated, and that it would not be equitable to aim to treat 
100% of patients with one disease while limiting treatment to 
only 10 - 20% of patients with other diseases that could also 
be effectively ameliorated. However, it is often impossible 
to obtain consensus on what is rational and fair when health 
services must compete for scarce resources. A process for 
allocating limited medical resources, called ‘Accountability 
for Reasonableness’ (A4R), can be of value here.21 Four 
conditions must be satisfied: (i) relevant reasons must be given 
for priorities being set; (ii) transparency must be ensured 
by involving representatives of all relevant stakeholders in 
the decision-making process and publicising the details of 
the process; (iii) there should be opportunities to appeal any 
decision; and (iv) leadership should be provided to drive the 
process and ensure accountability. 
Using an adaptation of this process, some South African 
academic institutions have been increasingly involved with 
public sector administrators and clinicians to develop ethically 
acceptable province-wide resource allocation policies for a 
range of critical health services (e.g. access to intensive care, 
renal dialysis and transplantation, etc.).22 The initial results 
are showing promise, and we recommend that this process be 
extended and adapted for use more centrally within provincial 
health administrations and at the national level. 
While use of A4R would not solve all of the problems that 
arise when there are insufficient resources to provide the best 
possible care to all who need it, it would, we believe, help 
to allocate resources accountably and ethically in the face of 
mounting health care needs and an inability to do everything 
that could be done for all. The government has recognised the 
practical impossibility, given limited resources, of providing 
ARVs to 100% of those who need them. This is already the 
case for many life-saving treatments that are withheld when a 
disease is too advanced for effective and sustained responses to 
be achieved.  Given the need to treat disease populations in a 
non-discriminatory fashion, disease-specific programmes, such 
as those for HIV, should be designed with the additional goal 
of strengthening the public health infrastructure to increase the 
capacity to provide a decent package of care and treatment to 
all who need it.23 As the growing health needs of the nation’s 
HIV population are met, policy makers must ensure that other 
diseases are not neglected. 
Although we believe that it is vitally important for the 
government to adopt a rational process to accomplish the 
above goals, a better and more effective resource allocation 
process will not substitute for adequate funding. Health 
administrators, clinicians and activists must advocate for 
increased spending on health care and aggressively seek donor 
assistance to deal with a humanitarian crisis of monumental 
proportions caused by our HIV/AIDS pandemic. This will 
become critically important as spending for HIV inevitably 
escalates, especially if this targeted funding of HIV treatment 
is seen as displacing funding that is also needed to build 
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the health system’s capacity to provide decent medical care 
to all South Africans, many of whom are now inadequately 
served by a poorly managed, under-resourced health system. 
The tragedy of grossly inadequate health care for many 
draws attention to the shortcomings of a global political 
economy that encourages wastage, corruption and excessive 
greed that unfortunately also plague many nations.24 Facing 
unprecedented challenges, our health administrators must 
adopt new paradigms of thinking and action to cope with 
rising health demands in context of severely limited resources. 
Failure to meet these challenges will ensure that the already 
unacceptably wide gap between rich and poor South Africans 
will only widen. 
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